The article presents an updated clinical practice guideline for the diagnosis and management of Long COVID, a condition characterized by persistent symptoms and signs associated with COVID-19 lasting more than three months. The guideline is developed by a multidisciplinary team of experts from various medical fields, including infectious diseases, pulmonology, psychiatry, and neurology. It aims to provide comprehensive and evidence-based recommendations for the evaluation and treatment of Long COVID based on the latest research data up to June 2023. Key recommendations include: 1. **Definition and Epidemiology**: Long COVID is defined as symptoms persisting beyond three months after acute SARS-CoV-2 infection. The prevalence varies globally, with higher rates in non-hospitalized patients and those with mild infections. 2. **Risk Factors**: Females, older age, high BMI, smoking, and underlying conditions like anxiety, depression, and chronic diseases are associated with a higher risk of developing Long COVID. 3. **Clinical Features and Pathophysiology**: Long COVID can affect multiple organ systems and is associated with immune dysregulation, microbiota imbalance, autoimmunity, and neurological issues. 4. **Diagnosis**: The guideline provides detailed evaluation methods for various symptoms, including respiratory distress, chest pain, cough, fatigue, arthralgia, myalgia, headaches, cognitive impairment, anxiety, depression, sleep disorders, and more. 5. **Treatment**: Recommendations cover the management of each symptom, emphasizing the importance of a comprehensive approach that includes medical history, physical examination, blood tests, imaging studies, and functional tests. Vaccination and antiviral treatment during the acute phase are recommended to reduce the risk of developing Long COVID. The guideline is designed to assist clinicians in making informed decisions about the diagnosis and treatment of Long COVID, ensuring that patients receive appropriate and evidence-based care.The article presents an updated clinical practice guideline for the diagnosis and management of Long COVID, a condition characterized by persistent symptoms and signs associated with COVID-19 lasting more than three months. The guideline is developed by a multidisciplinary team of experts from various medical fields, including infectious diseases, pulmonology, psychiatry, and neurology. It aims to provide comprehensive and evidence-based recommendations for the evaluation and treatment of Long COVID based on the latest research data up to June 2023. Key recommendations include: 1. **Definition and Epidemiology**: Long COVID is defined as symptoms persisting beyond three months after acute SARS-CoV-2 infection. The prevalence varies globally, with higher rates in non-hospitalized patients and those with mild infections. 2. **Risk Factors**: Females, older age, high BMI, smoking, and underlying conditions like anxiety, depression, and chronic diseases are associated with a higher risk of developing Long COVID. 3. **Clinical Features and Pathophysiology**: Long COVID can affect multiple organ systems and is associated with immune dysregulation, microbiota imbalance, autoimmunity, and neurological issues. 4. **Diagnosis**: The guideline provides detailed evaluation methods for various symptoms, including respiratory distress, chest pain, cough, fatigue, arthralgia, myalgia, headaches, cognitive impairment, anxiety, depression, sleep disorders, and more. 5. **Treatment**: Recommendations cover the management of each symptom, emphasizing the importance of a comprehensive approach that includes medical history, physical examination, blood tests, imaging studies, and functional tests. Vaccination and antiviral treatment during the acute phase are recommended to reduce the risk of developing Long COVID. The guideline is designed to assist clinicians in making informed decisions about the diagnosis and treatment of Long COVID, ensuring that patients receive appropriate and evidence-based care.